Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Correction: An oral keratinocyte life cycle model identifies novel host genome regulation by human papillomavirus 16 relevant to HPV positive head and neck cancer.

Evans MR, James CD, Loughran O, Nulton TJ, Wang X, Bristol ML, Windle B, Morgan IM.

Oncotarget. 2019 May 14;10(35):3312. doi: 10.18632/oncotarget.26962. eCollection 2019 May 14. No abstract available.

2.

PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.

Hatterschide J, Bohidar AE, Grace M, Nulton TJ, Kim HW, Windle B, Morgan IM, Munger K, White EA.

Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7033-7042. doi: 10.1073/pnas.1819534116. Epub 2019 Mar 20.

PMID:
30894485
3.

Werner Helicase Control of Human Papillomavirus 16 E1-E2 DNA Replication Is Regulated by SIRT1 Deacetylation.

Das D, Bristol ML, Smith NW, James CD, Wang X, Pichierri P, Morgan IM.

MBio. 2019 Mar 19;10(2). pii: e00263-19. doi: 10.1128/mBio.00263-19.

4.

Human Papillomavirus 16 E2 Regulates Keratinocyte Gene Expression Relevant to Cancer and the Viral Life Cycle.

Evans MR, James CD, Bristol ML, Nulton TJ, Wang X, Kaur N, White EA, Windle B, Morgan IM.

J Virol. 2019 Feb 5;93(4). pii: e01941-18. doi: 10.1128/JVI.01941-18. Print 2019 Feb 15.

PMID:
30518656
5.

Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.

Shaikh MH, Idris A, Johnson NW, Fallaha S, Clarke DTW, Martin D, Morgan IM, Gabrielli B, McMillan NAJ.

Oral Oncol. 2018 Nov;86:105-112. doi: 10.1016/j.oraloncology.2018.09.006. Epub 2018 Sep 19.

PMID:
30409290
6.

Patients with integrated HPV16 in head and neck cancer show poor survival.

Nulton TJ, Kim NK, DiNardo LJ, Morgan IM, Windle B.

Oral Oncol. 2018 May;80:52-55. doi: 10.1016/j.oraloncology.2018.03.015. Epub 2018 Mar 30.

7.

An oral keratinocyte life cycle model identifies novel host genome regulation by human papillomavirus 16 relevant to HPV positive head and neck cancer.

Evans MR, James CD, Loughran O, Nulton TJ, Wang X, Bristol ML, Windle B, Morgan IM.

Oncotarget. 2017 Jun 1;8(47):81892-81909. doi: 10.18632/oncotarget.18328. eCollection 2017 Oct 10.

8.
9.

Integration of Human Papillomavirus Genomes in Head and Neck Cancer: Is It Time to Consider a Paradigm Shift?

Morgan IM, DiNardo LJ, Windle B.

Viruses. 2017 Aug 3;9(8). pii: E208. doi: 10.3390/v9080208. Review.

10.

Calcein represses human papillomavirus 16 E1-E2 mediated DNA replication via blocking their binding to the viral origin of replication.

Das D, Smith NW, Wang X, Richardson SL, Hartman MCT, Morgan IM.

Virology. 2017 Aug;508:180-187. doi: 10.1016/j.virol.2017.04.020. Epub 2017 May 29.

11.

The Deacetylase SIRT1 Regulates the Replication Properties of Human Papillomavirus 16 E1 and E2.

Das D, Smith N, Wang X, Morgan IM.

J Virol. 2017 Apr 28;91(10). pii: e00102-17. doi: 10.1128/JVI.00102-17. Print 2017 May 15.

12.

Analysis of The Cancer Genome Atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma.

Nulton TJ, Olex AL, Dozmorov M, Morgan IM, Windle B.

Oncotarget. 2017 Mar 14;8(11):17684-17699. doi: 10.18632/oncotarget.15179.

13.

DNA Damage Reduces the Quality, but Not the Quantity of Human Papillomavirus 16 E1 and E2 DNA Replication.

Bristol ML, Wang X, Smith NW, Son MP, Evans MR, Morgan IM.

Viruses. 2016 Jun 22;8(6). pii: E175. doi: 10.3390/v8060175.

14.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.

Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC.

Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.

15.

Failure to interact with Brd4 alters the ability of HPV16 E2 to regulate host genome expression and cellular movement.

Gauson EJ, Wang X, Dornan ES, Herzyk P, Bristol M, Morgan IM.

Virus Res. 2016 Jan 4;211:1-8. doi: 10.1016/j.virusres.2015.09.008. Epub 2015 Sep 10.

16.

Evidence supporting a role for TopBP1 and Brd4 in the initiation but not continuation of human papillomavirus 16 E1/E2-mediated DNA replication.

Gauson EJ, Donaldson MM, Dornan ES, Wang X, Bristol M, Bodily JM, Morgan IM.

J Virol. 2015 May;89(9):4980-91. doi: 10.1128/JVI.00335-15. Epub 2015 Feb 18.

17.

Levels of the E2 interacting protein TopBP1 modulate papillomavirus maintenance stage replication.

Kanginakudru S, DeSmet M, Thomas Y, Morgan IM, Androphy EJ.

Virology. 2015 Apr;478:129-35. doi: 10.1016/j.virol.2015.01.011. Epub 2015 Feb 7.

18.

Regulation of human genome expression and RNA splicing by human papillomavirus 16 E2 protein.

Gauson EJ, Windle B, Donaldson MM, Caffarel MM, Dornan ES, Coleman N, Herzyk P, Henderson SC, Wang X, Morgan IM.

Virology. 2014 Nov;468-470:10-18. doi: 10.1016/j.virol.2014.07.022. Epub 2014 Aug 16.

19.
20.

An interaction between human papillomavirus 16 E2 and TopBP1 is required for optimum viral DNA replication and episomal genome establishment.

Donaldson MM, Mackintosh LJ, Bodily JM, Dornan ES, Laimins LA, Morgan IM.

J Virol. 2012 Dec;86(23):12806-15. doi: 10.1128/JVI.01002-12. Epub 2012 Sep 12.

21.

Human papillomavirus 16 E2 stability and transcriptional activation is enhanced by E1 via a direct protein-protein interaction.

King LE, Dornan ES, Donaldson MM, Morgan IM.

Virology. 2011 May 25;414(1):26-33. doi: 10.1016/j.virol.2011.03.002. Epub 2011 Apr 2.

22.

The human and canine TERT promoters function equivalently in human and canine cells.

Arendt ML, Nasir L, Morgan IM.

Vet Comp Oncol. 2010 Dec;8(4):310-6. doi: 10.1111/j.1476-5829.2010.00227.x.

PMID:
21062413
23.

Human papillomavirus E1 and E2 mediated DNA replication is not arrested by DNA damage signalling.

King LE, Fisk JC, Dornan ES, Donaldson MM, Melendy T, Morgan IM.

Virology. 2010 Oct 10;406(1):95-102. doi: 10.1016/j.virol.2010.06.033. Epub 2010 Jul 31.

24.

Adenovirus 12 E4orf6 inhibits ATR activation by promoting TOPBP1 degradation.

Blackford AN, Patel RN, Forrester NA, Theil K, Groitl P, Stewart GS, Taylor AM, Morgan IM, Dobner T, Grand RJ, Turnell AS.

Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12251-6. doi: 10.1073/pnas.0914605107. Epub 2010 Jun 21.

25.

A novel two-step transcriptional activation system for gene therapy directed toward epithelial cells.

Arendt ML, Nasir L, Morgan IM.

Mol Cancer Ther. 2009 Dec;8(12):3244-54. doi: 10.1158/1535-7163.MCT-09-0543.

26.

The human papillomavirus 16 E2 protein is stabilised in S phase.

Johansson C, Graham SV, Dornan ES, Morgan IM.

Virology. 2009 Nov 25;394(2):194-9. doi: 10.1016/j.virol.2009.08.046. Epub 2009 Sep 24.

27.

Oncolytic gene therapy for canine cancers: teaching old dog viruses new tricks.

Arendt M, Nasir L, Morgan IM.

Vet Comp Oncol. 2009 Sep;7(3):153-61. doi: 10.1111/j.1476-5829.2009.00187.x.

PMID:
19691644
28.

Small interfering RNA targeting bovine papillomavirus type 1 E2 induces apoptosis in equine sarcoid transformed fibroblasts.

Gobeil PA, Yuan Z, Gault EA, Morgan IM, Campo MS, Nasir L.

Virus Res. 2009 Oct;145(1):162-5. doi: 10.1016/j.virusres.2009.06.019. Epub 2009 Jul 15.

PMID:
19615418
29.

Presence of beta human papillomaviruses in nonmelanoma skin cancer from organ transplant recipients and immunocompetent patients in the West of Scotland.

Mackintosh LJ, de Koning MN, Quint WG, Ter Schegget J, Morgan IM, Herd RM, Campo MS.

Br J Dermatol. 2009 Jul;161(1):56-62. doi: 10.1111/j.1365-2133.2009.09146.x. Epub 2009 Mar 30.

PMID:
19416244
30.

The detection of Bovine Papillomavirus type 1 DNA in flies.

Finlay M, Yuan Z, Burden F, Trawford A, Morgan IM, Campo MS, Nasir L.

Virus Res. 2009 Sep;144(1-2):315-7. doi: 10.1016/j.virusres.2009.04.015. Epub 2009 May 4.

PMID:
19409942
31.

Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.

Morris JS, Nixon C, King OJ, Morgan IM, Philbey AW.

Vet J. 2009 Mar;179(3):422-9. doi: 10.1016/j.tvjl.2007.10.025. Epub 2008 Mar 7.

PMID:
18314357
32.

P53 represses human papillomavirus type 16 DNA replication via the viral E2 protein.

Brown C, Kowalczyk AM, Taylor ER, Morgan IM, Gaston K.

Virol J. 2008 Jan 11;5:5. doi: 10.1186/1743-422X-5-5.

33.

Aberrant expression of TopBP1 in breast cancer.

Going JJ, Nixon C, Dornan ES, Boner W, Donaldson MM, Morgan IM.

Histopathology. 2007 Mar;50(4):418-24.

PMID:
17448016
34.
35.

Equine sarcoids are not induced by an infectious cell line.

Gobeil P, Gault EA, Campo MS, Gow J, Morgan IM, Nasir L.

Equine Vet J. 2007 Mar;39(2):189-91. No abstract available.

PMID:
17378450
36.

Immunohistochemical expression of TopBP1 in feline mammary neoplasia in relation to histological grade, Ki67, ERalpha and p53.

Morris JS, Nixon C, Bruck A, Nasir L, Morgan IM, Philbey AW.

Vet J. 2008 Feb;175(2):218-26. Epub 2007 Mar 1.

PMID:
17336111
37.

TopBP1 regulates human papillomavirus type 16 E2 interaction with chromatin.

Donaldson MM, Boner W, Morgan IM.

J Virol. 2007 Apr;81(8):4338-42. Epub 2007 Feb 7.

38.

TopBP1 contains a transcriptional activation domain suppressed by two adjacent BRCT domains.

Wright RH, Dornan ES, Donaldson MM, Morgan IM.

Biochem J. 2006 Dec 15;400(3):573-82.

39.

Detection and quantitation of HPV DNA replication by Southern blotting and real-time PCR.

Morgan IM, Taylor ER.

Methods Mol Med. 2005;119:349-62.

PMID:
16350410
40.

Human papillomavirus 16 L2 inhibits the transcriptional activation function, but not the DNA replication function, of HPV-16 E2.

Okoye A, Cordano P, Taylor ER, Morgan IM, Everett R, Campo MS.

Virus Res. 2005 Mar;108(1-2):1-14.

PMID:
15681049
41.

SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells.

McPhillips MG, Veerapraditsin T, Cumming SA, Karali D, Milligan SG, Boner W, Morgan IM, Graham SV.

J Virol. 2004 Oct;78(19):10598-605.

42.
43.

The fidelity of HPV16 E1/E2-mediated DNA replication.

Taylor ER, Dornan ES, Boner W, Connolly JA, McNair S, Kannouche P, Lehmann AR, Morgan IM.

J Biol Chem. 2003 Dec 26;278(52):52223-30. Epub 2003 Oct 14.

44.

UVB irradiation reduces the half-life and transactivation potential of the human papillomavirus 16 E2 protein.

Taylor ER, Boner W, Dornan ES, Corr EM, Morgan IM.

Oncogene. 2003 Jul 17;22(29):4469-77.

PMID:
12881703
45.
46.

A Functional interaction between the human papillomavirus 16 transcription/replication factor E2 and the DNA damage response protein TopBP1.

Boner W, Taylor ER, Tsirimonaki E, Yamane K, Campo MS, Morgan IM.

J Biol Chem. 2002 Jun 21;277(25):22297-303. Epub 2002 Apr 4.

47.

Quercetin, E7 and p53 in papillomavirus oncogenic cell transformation.

Beniston RG, Morgan IM, O'Brien V, Campo MS.

Carcinogenesis. 2001 Jul;22(7):1069-76.

PMID:
11408351
49.

An enhanced epithelial response of a papillomavirus promoter to transcriptional activators.

Vance KW, Campo MS, Morgan IM.

J Biol Chem. 1999 Sep 24;274(39):27839-44.

50.

The bovine papillomavirus type 4 long control region contains an epithelial specific enhancer.

Morgan IM, Grindlay GJ, Campo MS.

J Gen Virol. 1999 Jan;80 ( Pt 1):23-7.

PMID:
9934679

Supplemental Content

Loading ...
Support Center